0000905718-18-000997.txt : 20181227
0000905718-18-000997.hdr.sgml : 20181227
20181227161228
ACCESSION NUMBER: 0000905718-18-000997
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181221
FILED AS OF DATE: 20181227
DATE AS OF CHANGE: 20181227
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Abingworth LLP
CENTRAL INDEX KEY: 0001397144
STATE OF INCORPORATION: X0
FISCAL YEAR END: 0630
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36593
FILM NUMBER: 181254830
BUSINESS ADDRESS:
STREET 1: 38 JERMYN STREET
CITY: LONDON
STATE: X0
ZIP: SW1Y 6DN
BUSINESS PHONE: 44 (0)20 7534 1500
MAIL ADDRESS:
STREET 1: 38 JERMYN STREET
CITY: LONDON
STATE: X0
ZIP: SW1Y 6DN
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SOLENO THERAPEUTICS INC
CENTRAL INDEX KEY: 0001484565
STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
IRS NUMBER: 770523891
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1235 RADIO ROAD
STREET 2: SUITE 110
CITY: REDWOOD CITY
STATE: CA
ZIP: 94065
BUSINESS PHONE: 650-213-8444
MAIL ADDRESS:
STREET 1: 1235 RADIO ROAD
STREET 2: SUITE 110
CITY: REDWOOD CITY
STATE: CA
ZIP: 94065
FORMER COMPANY:
FORMER CONFORMED NAME: Capnia, Inc.
DATE OF NAME CHANGE: 20100219
3
1
soleno_fm3dec212018.xml
X0206
3
2018-12-21
0
0001484565
SOLENO THERAPEUTICS INC
SLNO
0001397144
Abingworth LLP
38 JERMYN STREET
LONDON
X0
SW1Y 6DN
UNITED KINGDOM
0
0
1
0
Common Stock
4669272
I
See Footnote
Warrant
2.00
2018-12-21
2023-12-21
Common Stock $.001 par value
233463
I
See Footnote
Stock Option (right to buy)
1.57
2028-12-21
Common Stock $.001 par value
20000
I
See Footnote
The shares are held by Abingworth Bioventures VII, LP ("Abingworth"). Abingworth Bioventures VII GP LP ("Abingworth GP") serves as the general partner of Abingworth. Abingworth General Partner VII LLP, serves as the general partner of Abingworth GP. Abingworth (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VII LLP) has delegated to Abingworth LLP ("ALLP"), all investment and dispositive power over the securities held by Abingworth. ALLP holds the reported securities indirectly through Abingworth. ALLP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, Abingworth or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
These options (the "Options") were granted to Dr. Andrew Sinclair ("Sinclair"), a Partner of ALLP. ALLP provides advisory services to Abingworth. Under an agreement between Sinclair and ALLP, Sinclair is deemed to hold the Options and any shares of common stock issuable upon exercise of the Options for the benefit of ABV VII, and must exercise the Options solely upon the direction of ALLP.
This option was granted on December 21, 2018 with respect to 20,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning on December 21, 2018.
/s/ John Heard
2018-12-27